Movement Alert｜Innovent Biologics Rises 3.78% in Regular Trading, Exclusive Licensing Agreement with Spero Therapeutics for Third-Generation Anti-CD40L Antibody

Market Focus07-15 09:38

On July 15, Innovent Biologics rose 3.78% in regular trading, trading at HKD 93.75/share, with turnover of HKD 340 million.

The movement was driven by the announcement on July 14 that Innovent Biologics entered into an exclusive licensing agreement with Spero Therapeutics for IBI355 (SP001), a third-generation anti-CD40L monoclonal antibody ready for Phase II clinical development. Spero plans to initiate a Phase II study of IBI355 in IgG4-related disease in Q2 next year, while Innovent plans to launch a Phase II trial for Sjogren's disease in China by early next year.

This deal adds to Innovent's expanding partnership portfolio, following recent commercial agreements with Eli Lilly for Verzenios in mainland China and collaboration with Pfizer. Multiple brokerages maintain Buy ratings on the stock, with target prices ranging from HKD 119.2 to HKD 134.5. Bank of America recently raised its target price to HKD 119.2, citing an active licensing transaction environment and robust internal R&D capabilities.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1165017200?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-15 09:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1165017200","market":"us","top_or_hot":-1,"title":"Movement Alert｜Innovent Biologics Rises 3.78% in Regular Trading, Exclusive Licensing Agreement with Spero Therapeutics for Third-Generation Anti-CD40L Antibody","media":"Market Focus","content":"<p><p>On July 15, Innovent Biologics rose 3.78% in regular trading, trading at HKD 93.75/share, with turnover of HKD 340 million.</p><p>The movement was driven by the announcement on July 14 that Innovent Biologics entered into an exclusive licensing agreement with Spero Therapeutics for IBI355 (SP001), a third-generation anti-CD40L monoclonal antibody ready for Phase II clinical development. Spero plans to initiate a Phase II study of IBI355 in IgG4-related disease in Q2 next year, while Innovent plans to launch a Phase II trial for Sjogren's disease in China by early next year.</p><p>This deal adds to Innovent's expanding partnership portfolio, following recent commercial agreements with Eli Lilly for Verzenios in mainland China and collaboration with Pfizer. Multiple brokerages maintain Buy ratings on the stock, with target prices ranging from HKD 119.2 to HKD 134.5. Bank of America recently raised its target price to HKD 119.2, citing an active licensing transaction environment and robust internal R&D capabilities.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Innovent Biologics Rises 3.78% in Regular Trading, Exclusive Licensing Agreement with Spero Therapeutics for Third-Generation Anti-CD40L Antibody</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Innovent Biologics Rises 3.78% in Regular Trading, Exclusive Licensing Agreement with Spero Therapeutics for Third-Generation Anti-CD40L Antibody\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-15 09:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 15, Innovent Biologics rose 3.78% in regular trading, trading at HKD 93.75/share, with turnover of HKD 340 million.</p><p>The movement was driven by the announcement on July 14 that Innovent Biologics entered into an exclusive licensing agreement with Spero Therapeutics for IBI355 (SP001), a third-generation anti-CD40L monoclonal antibody ready for Phase II clinical development. Spero plans to initiate a Phase II study of IBI355 in IgG4-related disease in Q2 next year, while Innovent plans to launch a Phase II trial for Sjogren's disease in China by early next year.</p><p>This deal adds to Innovent's expanding partnership portfolio, following recent commercial agreements with Eli Lilly for Verzenios in mainland China and collaboration with Pfizer. Multiple brokerages maintain Buy ratings on the stock, with target prices ranging from HKD 119.2 to HKD 134.5. Bank of America recently raised its target price to HKD 119.2, citing an active licensing transaction environment and robust internal R&D capabilities.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01801","symbol_name":"信达生物","start_time":0,"source_url":"","article_id":"1165017200","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1165017200","pubTimestamp":1784079529,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 15, Innovent Biologics rose 3.78% in regular trading, trading at HKD 93.75/share, with turnover of HKD 340 million.The movement was driven by the announcement on July 14 that Innovent...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01801":"信达生物"},"translate_title":"动向提醒|信达生物常规交易涨3.78%，与Spero Therapeutics达成第三代抗CD40L抗体独家许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1},"content_text":"On July 15, Innovent Biologics rose 3.78% in regular trading, trading at HKD 93.75/share, with turnover of HKD 340 million.The movement was driven by the announcement on July 14 that Innovent Biologics entered into an exclusive licensing agreement with Spero Therapeutics for IBI355 (SP001), a third-generation anti-CD40L monoclonal antibody ready for Phase II clinical development. Spero plans to initiate a Phase II study of IBI355 in IgG4-related disease in Q2 next year, while Innovent plans to launch a Phase II trial for Sjogren's disease in China by early next year.This deal adds to Innovent's expanding partnership portfolio, following recent commercial agreements with Eli Lilly for Verzenios in mainland China and collaboration with Pfizer. Multiple brokerages maintain Buy ratings on the stock, with target prices ranging from HKD 119.2 to HKD 134.5. Bank of America recently raised its target price to HKD 119.2, citing an active licensing transaction environment and robust internal R&D capabilities.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1165017200","isCrawlerRequest":true}